Results 231 to 240 of about 35,569 (305)

Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival. [PDF]

AACE Endocrinol Diabetes
Reule S, Pickthorn S, Drake T, Ishani A, Foley R.   +4 more
europepmc   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Perioperative Glucagon-Like Peptide-1 Receptor Agonist Therapy and Postoperative Outcomes in Adult Foot and Ankle Surgery: A Scoping Review. [PDF]

Cureus
Zahed M, Alesawy AF, Elkohail A, Ghazi A, Fell A, Hashem M.   +5 more
europepmc   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study. [PDF]

Diabetes Obes Metab
Hisada H, Ikeuchi K, Tsuji Y, Yamamichi N, Kakushima N, Okushin K, Yakabi S, Takeuchi C, Ohki D, Mizutani H, Miura Y, Kubota D, Tsutsumi T, Fujishiro M.   +13 more
europepmc   +1 more source

Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate the 12‐month effectiveness and patient persistence of a semaglutide‐supported digital weight‐loss service (DWLS) in a real‐world German cohort. Methods This retrospective study analysed 4535 patients who initiated the Juniper Germany DWLS. Primary endpoints included 12‐month medication and data submission adherence (receiving ≥ 
Louis Talay, Jason Hom, Marilyn Tan, Neera Ahuja   +3 more
wiley   +1 more source

Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. [PDF]

J Med Chem
Wu B, Falsey JR, Netirojjanakul C, Herberich B, Holder JR, Sham K, Aral J, Forsythe N, Walker KW, Lu SC, Hager T, Stanislaus S, Komorowski R, Atangan L, Achmatowicz M, Romanini D, Weeraratne D, Miranda LP, Véniant MM, Cheng Y.   +19 more
europepmc   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak, Martin Bøg, Theiss Bendixen, Rohan Chowdhury, Phoebe Cowley, Christian Laugesen, Naveen Rathor, Robert F. Kushner   +7 more
wiley   +1 more source

Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis. [PDF]

Neurol Int
Rai P, Mandel D, Bathla G, Dhaduk V, Rajeev R, Kakadiya J, Chen HA, Salim HA, Azzam AY, Essibayi MA, Connolly B, Buzzelli M, Yedavalli VS, Khan M, Dmytriw AA, Altschul DJ, McIntyre MK, Colasurdo M, Malhotra A, Gandhi D, Lakhani DA.   +20 more
europepmc   +1 more source

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen   +7 more
wiley   +1 more source